MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.19 -1.65

Buy Sell

Overview

Share price change

24h

Current

Min

1.17

Max

1.24

Key metrics
By Trading Economics
Income	-124K -32M
Sales	-372K 1.4M
EPS	-0.27
Profit margin	-2,364.792
Employees	161
EBITDA	-13M -42M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+63.93% upside

Dividends
By Dow Jones
Next Earnings	11 maj 2026

Market Stats
By TradingEconomics
Market Cap	-43M 131M
Previous open	2.84
Previous close	1.19

News Sentiment

By Acuity

50%

170 / 349 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

6 kwi 2026, 23:17 UTC

Earnings

Samsung Forecasts Record First-Quarter Operating Profit

6 kwi 2026, 23:00 UTC

Hot Stocks

Stocks to Watch: Health Insurers, Mawson, Owlet

6 kwi 2026, 22:13 UTC

Major Market Movers

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6 kwi 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6 kwi 2026, 17:09 UTC

Major Market Movers

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6 kwi 2026, 16:56 UTC

Major News Events

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6 kwi 2026, 14:47 UTC

Major Market Movers

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7 kwi 2026, 00:00 UTC

Major News Events

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6 kwi 2026, 23:58 UTC

Market Talk

Major News Events

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6 kwi 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6 kwi 2026, 23:36 UTC

Market Talk

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6 kwi 2026, 23:15 UTC

Market Talk

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6 kwi 2026, 22:52 UTC

Market Talk

Global Equities Roundup: Market Talk

6 kwi 2026, 22:52 UTC

Market Talk

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6 kwi 2026, 22:14 UTC

Market Talk

Correction to Live Cattle Futures Article

6 kwi 2026, 20:56 UTC

Market Talk

Mexican Private Consumption Fell in January -- Market Talk

6 kwi 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

6 kwi 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 kwi 2026, 19:58 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 kwi 2026, 19:58 UTC

Market Talk

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6 kwi 2026, 19:11 UTC

Market Talk

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6 kwi 2026, 19:06 UTC

Market Talk

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6 kwi 2026, 19:03 UTC

Market Talk

Global Energy Roundup: Market Talk

6 kwi 2026, 19:03 UTC

Market Talk

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6 kwi 2026, 18:36 UTC

Acquisitions, Mergers, Takeovers

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 kwi 2026, 17:59 UTC

Market Talk

Major News Events

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6 kwi 2026, 17:13 UTC

Acquisitions, Mergers, Takeovers

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 kwi 2026, 16:33 UTC

Market Talk

Oil Futures Steady as Market Awaits Trump -- Market Talk

6 kwi 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 kwi 2026, 14:59 UTC

Earnings

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

63.93% upside

12 Months Forecast

Average 2 USD 63.93%

High 2 USD

Low 2 USD

Based on 3 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

170 / 349 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.